All day
University of Chicago Center in Beijing
20th Floor, Culture Plaza
59A Zhong Guan Cun Street
Haidian District, Beijing
18
Organizers:
Beijing Medical Association Society of Oncology
University of Chicago Center in Beijing
Zhongguancun Jiutai Good Clinical Practice Union
Beijing Hospital
Assistant Organizers:
Zhongguancun Jiutai Good Clinical Practice Union Cellular Biologics Clinical Trial Committee
Apexell Medicine Research (Beijing) Co.,Ltd
About the Conference
Stem cell transplant is one of the most distinguished scientific developments in the 20th century; representing an important milestone for the treatment of hematologic malignancies. The Beijing transplant regimen as well as John Hopkin post-transplant cyclophosphamide regimen using haploidentical donors expands the donor options providing potential cure to many patients with hematologic malignancies. As one of the top medical centers in USA, University of Chicago Medical Center (UCMC) contributed haplo-cord stem cell transplant regimen to the transplant field, the Cellular Therapy program at UCMC has been among the first centers to offer the two commercially available CART products to patients in the Chicago area. Currently, the program has many cellular therapy clinical trials ongoing to treat lymphoma, multiple myeloma, acute leukemia and various solid tumors. This meeting invited many leading Chinese scientists and hematologist/oncologists in the field of cellular therapy and cancer treatment to share academic ideas and promote international collaboration between the Chinese investigators and the faculties at UCMC. All the colleagues who are interested in cellular and immunotherapy are welcome to attend the meeting.
Agenda
Saturday morning, May 18th / 5月18日上午
Main Conference Venue / 主会场
(Simultaneous Translation will be provided /提供中英文同声传译)
7:30-8:30
Registration
8:30-8:40
Opening Remarks
Jie Ma, Beijing Hospital
Hongtao Liu, Section of Hematology / Oncology, UChicago Medicine
8:40-9:10
Haploidentical Transplantation: Some Concept, Different Results
Xiaojun Huang, Chairman, Peking University Institute of Hematology、 Director, Department of Hematology, Peking University People’s Hospital
9:10-9:40
The Past, Current and the Future of Stem Cell Transplant and Cellular Therapy
Michael Bishop, Section of Hematology / Oncology, UChicago Medicine
9:40-10:10
State-of-the Art of Treatment of ALL: Molecular, Antibody and Cellular Targeting to Eradicate MRD ALL
MRD Wendy Stock, Section of Hematology / Oncology, UChicago Medicine
10:10-10:30
Discussion
10:30-10:40
Tea Break
10:40-11:10
Immunotherapy for Renal Cell Carcinoma
Kan Gong, Peking University First Hospital
11:10-11:40
Clinical Study in Cellular Immunotherapy for Solid Tumors
Jie Ma, Beijing Hospital
11:40-12:10
Progress in Immunotherapy for Prostate Cancer
Wei Wang, Beijing Tongren Hospital
12:10-12:30
Discussion
12:30-13:30
Lunch (For all participants)
Saturday afternoon, May 18th（Main Conference Place）
Breakout Session I: Hematology
(Simultaneous Translation will be provided /提供中英文同声传译)
13:30-13:40
Opening Remarks
13:40-14:10
Donor-derived HCMV-specific T Cells Therapy for CMV Infection Post Allogenic Stem Cell
Xiangyu Zhao, Section of Hematology /Peking University Institute of Hematology
14:10-14:40
Checkpoint Blockade Therapy for Lymphoma
Justin Kline, Section of Hematology/Oncology (Cancer) UChicago Medicine
14:40-15:10
Road to Improve the Outcomes of AML with Poor Gene Mutation-experience from A Single Center
Daihong Liu, Section of Hematology, Chinese PLA General Hospital (PLA 301 Hospital)
15:10-15:30
Discussion
15:30-15:40
Tea Break
15:40-16:10
Immunotherapies in Hematologic Malignancies
Hongtao Liu, Section of Hematology / Oncology, UChicago Medicine
16:10-16:40
CD19CAR-T for Treatment of B cell ALL Chinese Experience
Peihua Lu, Institute of Hematology, Lu Daopei Hospital
16:40-17:10
The CART Treatment for Lymphomas
Peter Riedell, Section of Hematology / Oncology UChicago Medicine
17:10-17:30
Discussion
Saturday afternoon, May 18th（Large Classroom）
Breakout Session II: Urology
13:30-13:40
Opening Remark
Kan Gong, Peking University First Hospital
13:40-14:10
Experience in Immunotherapy of Urinary Tumors
Haixing Mai, PLA Fifth Medical Center
14:10-14:40
Application of PSMA-PET in the Diagnosis and Treatment of Prostate Cancer
Ning Zhang, Beijing Cancer Hospital, Peking University
14:40-15:10
Discussion
15:10-15:20
Tea Break
15:20-15:50
Application of Immunotherapy for Urothelial Carcinoma
Gangyue Hao, Beijing Friendship Hospital
15:50-16:20
Management of Adverse Immune Reactions
Xinrong Fan, Peking Union Medical College Hospital
16:20-16:50
Discussion
16:50-17:20
Conclusion
Xin Ma , Chinese PLA General Hospital (PLA 301 Hospital)
Saturday afternoon, May 18th（Lecture Hall）
Breakout Session III: Clinical Research Management Training
13:30-13:40
Opening Remarks
13:40-14:25
Principles and Design of Cellular Immunotherapy of Cancer
Weidong Han, Chinese PLA General Hospital (PLA 301 Hospital)
14:25-15:10
Clinical Trial Design for Cellular Therapy
Yi Zhang, The First Affiliated Hospital of Zhengzhou University
15:10-15:20
Tea Break
15:20-16:05
Thinking and Practice of Solid Tumor Immunotherapy
Jiuwei Cui, The First Affiliated Hospital of Jilin University
16:05-16:50
Process Control and Common Problems in Clinical Trials
Kexin Li, Beijing Hospital
16:50-17:35
Quality Standard of Clinical Viral Vectors
M. Jaysson Eicholtz, Apexell Medicine